Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions:   Behavioral: Assessment;   Procedure: Biospecimen Collection;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 5, 2021Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments